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Introduction 
 Stroke or cerebrovascular disease (CVD) is the second leading cause of 
death worldwide, with 6.2 million deaths in 2008, and the leading cause of 
disability in developed countries. There are, in average, 200 new stroke cases 
per 100,000 people per year 1.  
 After a first stroke the cumulative risk of a new vascular event, know as 
recurrence, is 11.1% at first year, 26.4% over the next 5 years and 39.2% at 10 
years2. As platelets play a major role in thrombus formation, to try to prevent 
new vascular episodes (secondary prevention), antithrombotic and antiplatelet 
drugs are used3. The most widely used antiplatelets are acetylsalicylic acid 
(ASA) and clopidogrel. 
 Despite the clear benefits demonstrated by  antiplatelet therapy, platelet 
reactivity is variable and patients do not respond to this therapy evenly. Overall, 
patients mortality is reduced only by 18%  and the number of patients with 
disability is reduced by 25% which are reductions rates far from satisfactory. In 
fact 10-20%4 of patients treated with ASA or clopidogrel have new vascular 
events. This phenomenon may be due to drug resistance by the patient. Drug 
resistance is defined as a  failure in platelet inhibition activity despite a correct 
antiplatelet therapy.  
 After a first stroke approximately 60% of patients receive antiplatelet 
therapy5,6, for this reason, it's important to recognize the elements associated 
with drug resistance, in order to personalize the treatment to each patient. 
Therefore, in recent years, genetic studies have been performed to find genes 
associated with patient's resistance to antiplatelet treatment.  
 In the “omics” era Genome-wide association studies (GWAS) have been 
widely used to find polymorphisms associated with human diseases and 
pharmacogenetics. GWA studies have been more successful in finding new 
associations with complex diseases compared to classical candidate gene 
strategies. Pharmacogenetic studies in clopidogrel resistance, using candidate 
gene studies, have found polymorphisms in Cytochrome P450 genes  mainly at 
2C19 subtype (CYP2C19)7 and some others. Later GWAS in Amish population8 
also found  that CYP2C19*2 genotype was associated with diminished platelet 
response to clopidogrel treatment and poorer cardiovascular outcomes.   
 But phenotypes are not always defined only by the sequence of DNA 
sequence9 and GWAS, despite being able to find Cytochrome P450 genes 
association, have not shown clear associations between polymorphisms and 
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vascular resistance. Epigenetic studies open a new field to identify new genes 
and biomarkers associated with antiplatelet resistance treatment. 
 Epigenetics refer to the stable, heritable and reversible modifications in 
DNA associated with transcriptional regulation without altering the nucleotide 
sequence9. Epigenetic processes such as DNA methylation (DNAm), histone 
acetylation/deacetylation, non coding mRNA expression and chromatin 
conformational changes10,  are essential for normal cellular development and 
differentiation. Also epigenetic changes can be modulated by environmental 
factors, and have been related to some monogenic and complex human 
diseases11,12. Most DNAm studies have mainly been performed in the context of 
Cancer research12,13,14. Other studies on epigenetics dial with are aging effects 
on methylation patterns and age related diseases15,16, tobacco smoking impact 
on pregnancy and DNAm changes17,18. There are few studies in non-malignant 
common complex diseases there are few studies,  obesity19, diabetes mellitus20, 
ulcerative colitis21. 
 The major advances in epigenetics have been made in the field of DNA 
methylation. Epigenome-wide association studies (EWAS) use the same 
strategy of GWAS but for epigenetic modification. These studies use array-
based genotyping technology, with a previous bisulfite conversion, to detect the 
methylation levels at CpG islands across genome. EWAS are hypothesis free 
approaches that work in a high throughput basis with  methylation arrays which 
are currently able to analyze up to 450.000 CpG islands. EWA studies of human 
diseases are becoming increasingly common in the last few years. 
 The Illumina Infinium HumanMethylation450 BeadChip with over 450.000 
methylation sites per sample at single-nucleotide resolution, more than 98% of 
reproducibility for technical replicates and a PCR-free protocol22,23 is the most 
widely used technology for EWAS nowadays. The 450K BeadChip feature two 
different types of assays, Infinium I design employs two bead types per CpG 
site, one for the methylated and one for the unmethylated states, while Infinium 
II assay design uses just one bead type for both conditions. The methylation 
level is then estimated based on the measured intensities (Equation 1), ranging 
from 0 to 1 (β-value). Beta-values from 0.6 to 1 are considered as 
hypermethylated levels, and Beta-values from 0 to 0.4 are considered as 
hipomethylated levels22,23,24. 
 
Equation 1: Methylation levels are measures by the ratio of the methylation probe intensity and the overall 
intensity 
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 In the present study an epigenetic approach in pharmacogenetics, 42 
patients with a previous stroke and clopidogrel administration, were assessed in 
order to find differential methylation levels between those who shoved 
resistance and those who did not. 
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Objectives 
Main Objective: 
Determine whether there is a different methylation pattern among ischemic 
stroke patients associated with resistance to clopidogrel treatment. 
Secondary Objective: 
1. Explore the altered metabolic pathways involved in clopidogrel resistance. 
2. Standardize the epigenetic data analysis in our laboratory. 
3. Selection of the genetic platform to perform the replication analysis. 
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Methods 
Samples Selection. 
 In total, 42 individuals from the GRECAS study (Genotyping Risk and 
Efficacy of Clopidogrel or Aspirin following Stroke) were selected. The GRECAS 
individuals are patients with a previous ischemic stroke treated with clopidogrel 
or aspirin. The 21 cases and 21 controls were matched one-to-one by age, sex, 
TOAST classification, recruitment hospital and clopidogrel administration. All 
individuals were Caucasian, 35 of them were males and 7 were females (Table 
1). 
  Case Controls 
 N 21 (50%) 21 (50%) 
 Age 70 ± 8 71 ± 9 
G
e
n
de
r Male 18 (42,9%) 17 (40,5%) 
Female 3 (7,1%) 4 (9,5%) 
TO
AS
T*
 
Aterothrombotic 11 (26,2%) 11 (262%) 
Undetermined 5 (12%) 5 (12%) 
Unknown 1 (2,4) 1 (2,4) 
Lacunar 3 (7,1%) 3 (7,1%) 
 Hypertension 13 (31%) 16 (38,1%) 
 Dyslipidemia 12 (28,6%) 8 (19%) 
 Diabetes Mellitus 7 (16,7%) 8 (19%) 
Table 1: Characteristics of the study population.  
*TOAST classification of Ischemic stroke. 
DNA purification. 
 Total genomic DNA was extracted from whole blood samples using the 
Gentra Puregene Blood Kid (Quiagen, Hilden, Germany) following the 
manufacturer's instructions. The samples were maintained at -20ºC until the 
EWAS analysis.  
 DNA concentration of each subject was determined individually, by 
measuring ultraviolet (UV) light absorption at 260nm, with NanoDrop 2000 UV-
Vis Spectrophotometer (Thermo Scientific , Redwood City, CA, USA). Finally 
20µl at 50ng/µl of each samples were used to methylation analysis.  
Methylation analysis. 
 Genome-wide DNA methylation was assessed using the Infinium 
HumanMethylation450 BeadChip (Illumina Inc., San Diego Ca). This array 
based study, quantitatively measures more than 450,000 CpG sites at single 
nucleotide resolution with a 99% coverage of RefSeq Gene.  
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 First of all a Quality Control (QC) of all samples was performed to check 
the DNA integrity using Invitrogen E-Gel 1% Agarose Gels. No DNA samples 
showed fragmentation or poor quality. 
 Genomic DNA from 42 samples were bisulfite converted using Zymo EZ 
DNA MethylationTM Kit (Zymo Research, Orange Ca) following the 
manufacturer's procedure with alternative incubations conditions suggested for 
the llumina Infinium Methylation Assay. All samples were processed in a single 
working batch using the Illumina Infinium MSA4 protocol that includes 
amplification, fragmentation, hybridization and BeadChip scan. 
 For QC of the process, fluorescence data generated for each CpG locus 
was analyzed with the Ilumina GenomeStudio software package. Methylation 
data (beta-values) is combined with gene expression (p-values) profiling 
experiments within the same GenomeStudio, considering values lower than 
0.05 as of good quality. 
 
Quality control and normalization of the EWAS results 
 All pre-processing, correction and normalization steps were implemented 
by R (versions 3.15.1 and 3.0.1) with Bioconductor packages. All plots were 
produced using R functions. The pipline is a sequence (Appendix A) of R scripts 
(Table 2) adapted from the methylumi (version 2.6.1), lumi (version 2.12.0), 
wateRmelon (version 1.0.3) and minfi (version 1.6.0).  
 
R package Instruction Description 
methylumi methylumiR Load Illumina methylation data into a MethyLumiSet object. 
minfi densityPlot Density plots of methylation Beta values. 
watRmelon pfilter Filter data sets based on bead count and detection p-values 
minfi mdsPlot Multi-dimensional scaling (MDS) plots showing a 2-d projection of distances between samples. 
watRmelon dasen Calculate normalized betas from Illumina 450K methylation arrays. 
lumi estimateBetas Estimate methylation Beta-value matrix from eSet-class object (include methylated and unmethylated probe intensities) 
Table 2: Specific instructions used from each R package .  
 CpG sites with detection p-value  ≥ 0.05 in more than 1% of the samples 
and samples  with detection p-value ≥ 0.05 in more than 1% of the CpG sites 
were excluded prior to data analysis. CpG sites with beadcount < 3 in 5% of 
samples were excluded too. 
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 A cluster identification analysis was carried out to check if there was any 
subgroup on the sample or gender mismatch. 11.319 CpG islands being at X 
and Y chromosome and 65 SNP probes were excluded before quantile 
normalization of methylated and unmethylated results (β-values). After these 
quality checks, there were a total of 472.386 CpG islands and 41 samples.   
Data analysis. 
 To find the differentially methylated CpG sites (DMCs), β-values among 
control and case samples were analyzed using the non parametric Mann-
Whitney test for independent samples. We analyzed the 21 case samples 
(ischemic stroke subjects with resistance to clopidogrel) versus the 21 control 
samples  (ischemic stroke subjects without resistance to clopidogrel).  
 Haploview software was  used to create a Manhattan plot in other to find 
differentially methylated loci. 
Enrichment analysis 
 Finally, a basic biological function analysis was perform using NCBI data 
base, mainly PubMed (http://www.ncbi.nlm.nih.gov/pubmed), to find biological 
processes related to our findings in other studies. 
Replication study. 
 A bibliographical research about sequencing technologies to methylation 
studies was performed using technological information from different providers 
and also, PubMed data base to obtain scientific results of the technologies. 
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Results  
 In total 485.577CpG sites were assessed by Illumnia BeadChip 450k across 
whole genome in each of the 42 individual samples. The methylation intensities 
showed bimodal distributions when displayed across all proves (Figure.1), none of 
the samples show a different behaviour.  
 
Figure 1: Density Plot of the Methylation Beta values for all samples colored by sample 
group. Cases: green lines and controls: orange lines. All samples follow the same distribution. 
  After filtering the data based on the bead count (< 3 in 5% of samples) 
and p-values (1% >0.05), 1.848 sites and zero samples were removed. Illumina 
450k BeadChip have 65 SNP along the array, as quality controls, which were 
also removed. When performing a multidimensional scaling (MDS) no  
subgroups appeared in the sample (Figure.2), the graph show only two clusters 
representing males and females. One female sample that clustered into the 
males group, due to a genotyping error or a  typing error, was removed from the 
study. Finally 11.278 CpG sites located at X and Y chromosomes were also 
removed before the quantile normalization step (Figure.3).  
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Figure 2: Multidimensional Scaling plot of samples. Cases are in green color and controls in 
blue. Letter 'M' indicates a male and  letter 'F' indicates a female. Black arrow point a female 
sample clustered into male's group. 
 
 
Figure 3: Box plot of methylated and unmethylated log beta-value, before and after quantile 
normalization step. 
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 The analysis of differentially 
methylated CpG (DMCs) sites 
between cases and controls indicated 
a few number of CpG sites that were 
associated with new vascular events. 
In total 58 DMCs with p-val <0.05 
were found (Table.3), none of them 
was significant after FDR correction. 
Distribution of recurrence related 
DMCs (Figure 4) showed different 
behaviors between cases and 
controls. Case samples had a slightly 
higher average of hiper-methylation 
comparing to the control samples, in 
the upper range area. P-values for 
each CpG site were plotted in a 
Manhattan Plot to show the most 
significant loci (Figure 5). 
Table 3: 15 most significant diferentially 
methylted CpG and related genes. 
. 
 
Figure 4: Density Plot of the Methylation Beta values for 58 most significant differentially methylated 
CpGs. . The arrow indicates the hipermethylation of CpG sites of cases compared to controls. 
  
p-val TargetID Chr UCSC Ref. Gene Name 
8,54E-07 cg07925064 16 LOC100130015 
3,03E-06 cg06726262 17 ZNF286A 
6,97E-06 cg09332091 19 
 
6,97E-06 cg18002896 8 RHPN1 
9,58E-06 cg03548645 14 TRAF3 
1,12E-05 cg25236894 17 RPAIN 
1,12E-05 ch,18,400468R 18 
 
1,31E-05 cg09533145 5 ADAMTS2 
1,52E-05 cg18127204 17 MYOCD 
1,77E-05 cg01348374 3 
 
2,05E-05 cg12181407 5 
 
2,05E-05 cg14630099 6 HLA-DOA 
2,05E-05 cg18769818 11 ARAP1 
2,38E-05 cg03654504 1 GRIK3 
2,75E-05 cg10318528 4 SFRP2 
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Figure 4: Manhattan Plot of DMCs P-values across genome. Each spot represent a p-val and 
each color represents one chromosome. 
 The two most remarkable genes founds where, TRAF3 gene (cg03548645, 
p-val= 9,58e-06), and ADAMTS2 (cg09533145, p-val=1,31e-05 ). 
Replication. 
 To validate the 450k BeadChip data results, some sequencing technologies 
were assessed. The bibliographic research about, Sequenom - EpiTyper DNA 
methylation, Pyrosequencing for bisulfite converted samples and NGS for 
methylation studies, revealed no clear benefits for any of these technologies over 
the rest, and really all require high budgets. So the Sequenom - Epityper DNA 
methylation was chosen by economical conveniences. 
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Discursion 
 Clopidogrel, was ranked seventh among the most prescribed medications in 
United States in 2011, with more than 28 million prescriptions9,25. This drug is 
commonly prescribed in secondary prevention after stroke, however 21% of  
patients suffer experience recurrent ischemic events despite a good medication 
acherence26. Clopidogrel metabolism is highly variable and it has been related with 
patient genetic background,27. Increase our knowledge about Clopidogrel function 
and prevention of new vascular events promise to have a global impact on health 
promotion. 
 Pharmacogenetics offers the hope of greater personalized medicine, 
prescribing medications to those most likely to be benefit and avoid the use of 
certain medications in those most likely to be harmed by them. In addition, when 
several medication options are available, pharmacogenetics could help us to 
choose the one most appropriate for a particular individual. Good evidence of 
clinical usefulness of pharmacogenetics has been described for several treatments 
and diseases. Recently the Clinical Pharmacogenetics Implementation Consortium 
(CPIC)28, as the Food and Drugs Administration (FDA)29,30, proposed to genotype 
CYP2C19 before clopidogrel prescription. In addition, other Cytochrome P450 
polymosrphidms have been recommended to be genotyped before drug 
administration31. 
 In the present study, we have performed an epigenetic study to determine 
altered methylation CpG sites associated with clopidogrel resistant. We analyzed 
ischemic stroke patients treated with clopidogrel who presented new vascular 
events (cases) and those who do not had new vascular events (controls). 
 A group of 58 CpG sites were found significantly differentially methylated 
between cases and controls (Figure 4), although did not appear a clear locus that 
could indicate an affected gene (Figuere 5). However two of the most significant 
DMCs sites were next to TRAF3  and ADAMTS2 genes. 
 TRAF3 gene, TNF receptor-associated factor 3, encodes a protein member 
of the TNF receptor associated factor (TRAF) family. These proteins participates in 
the signal transduction of CD40 and TNFR important to de activation of immune 
response. It has been shown that patients suffering from cardiovascular disease 
exhibit increased levels of circulating and soluble CD40 ligand32,33. Zifang Song,et 
all described association between TRAF3 gene expression and CD40 levels in 
arterial injury34. Del Río-Espínola A. et all, also found an association between 
CD40 and the reclusion risk after fibrinolytic therapy during the acute phase of 
ischemic stroke35. Our results indicate that an increased expression of this gene 
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could be associated with a higher risk of new vascular events in ischemic stroke 
patients treated with clopidogrel. 
 ADAMTS2 gene, ADAM metallopeptidase with thrombospondin type 1 motif 
2, encodes a member of the ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs) protein family. ADAMTS designates a family of 19 secreted 
enzymes, that have a role in extracellular matrix degradation has previously been 
involved in various human biological processes, including connective tissue 
structure, cancer, coagulation, arthritis, angiogenesis and cell migration36. 
Mutations in ADAMTS13 gene lead to endothelial von Willebrand factor (VWF) 
platelet aggregation and then abnormal coagulation in targeted organs37. In relation 
to stroke a study of Arning and collegues observed a  clustering of association 
signals in 4 genes belonging to ADAMTS family of genes, including ADAMTS2, 
with pediatric stroke38. 
 The 'omics' studies require replication analysis to validate the results 
obtained in the discovery stage.. Therefore a replication study will be performed, 
using a new cohort of samples (n=300) in order to validate the results of the 
EWAS. The replication study will be performed using a different technology. We 
chose EpiTyper DNA methylation (Sequenom) due to it was a consistently  
technology with a low cost.. We will analyze 3-5 CpG sites in the new cohort of 300 
patients. 
 As a summary we found several interested genes that could be associated 
with clopidogrel resistance in ischemic stroke patients. To validate these results 
new studies will be performed in a new cohort of patients. 
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Conclusions 
 
 The present study has reported a group of CpG sites in clopidogrel 
resistance patients with higher percentage of methylation compared to non 
resistant patients. Two of the differentially methylated CpG sites found, are next to 
two genes associated with vascular diseases and inflammation (TRAF3 and 
ADAMTS2). To confirm these results, a new study in a different cohort is needed. 
 The customized R pipeline used for this study had showed good results 
compared to use one unique R package. Further EWAS in our lab will use this 
script as a standard.  
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Appendix 
Appendix A:   
 
# Paquetes # 
library("wateRmelon", lib.loc="/usr/local/lib/R/site-library") 
library("methylumi", lib.loc="/usr/local/lib/R/site-library") 
library("minfi", lib.loc="/usr/local/lib/R/site-library") 
library("lumi", lib.loc="/usr/local/lib/R/site-library") 
 
#Crear Objeto# 
EWAS <- methylumiR('FinalReport', sampleDescriptions=SamplesTable) 
 
EWAS # 485577 x 48 
 
## Eliminando Controles Sanos y Pools ## 
Eliminar<- c("MTE_CONIC97","MTE_CONIC112", "MTE_PoolA", 
"MTE_PoolB","MTE_PoolC","MTE_PoolD") 
EWAS <- EWAS[,!sampleNames(EWAS) %in% Eliminar] 
ewas <- as(EWAS, "MethylSet") 
data <- pData(EWAS) 
 
## Distribució de les Betas ## 
densityPlot(ewas, sampGroups = data$Group, main = "Methylation Density Distribution", 
xlab = "Methylation Level (Beta-val)") 
#qcReport(EWAS, sampNames=data$sampleID, sampGroups=data$Group, pdf="qcReport 
EWAS.pdf") 
 
# QC 1 # 
EWAS <- pfilter(EWAS) 
 
# Eliminar els 'proves' que son SNPs # 
rs <- c(grep("rs", featureNames(EWAS))) 
rs <- fData(EWAS)$TargetID[rs] 
EWAS <- EWAS[!fData(EWAS)$TargetID %in% rs,] 
ewas <- as(EWAS, "MethylSet") 
 
# QC 2# 
MDS <- cmdscale(dist(t(exprs(EWAS)[fData(EWAS)$CHR=='X',])),2) 
plot(MDS,main="MDS plot EWAS", pch=as.character(pData(EWAS)$Gender), las=1, cex=0.7, 
col=as.numeric(pData(EWAS)$Group)+2, xlab="V1",ylab="V2") 
legend("topright",c("case","control"),fill=c(3,4),cex=0.8) 
################################################## 
#ewas <- as(EWAS, "MethylSet") 
#data <- pData(EWAS) 
#mdsPlot(ewas, numPositions = 1000, sampGroups = data$Group,sampNames = data$Index) 
#mdsPlot(ewas, numPositions = 1000, sampGroups = data$Gender,sampNames = data$Index) 
#avgPval <- colMeans(pvals(EWAS)) 
#barplot(avgPval, ylab="P-Value",las=2, cex.axis=0.6, main="Average p-val EWAS") 
#################################################### 
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rm_mostres<- c("MTE_0001207") 
EWAS<- EWAS[,!sampleNames(EWAS) %in% rm_mostres] 
data <- pData(EWAS) 
 
# Eliminar CRH X e Y # 
XY_cpgs<-fData(EWAS)[fData(EWAS)$CHR=="X" | fData(EWAS)$CHR=="Y",] 
XY_cpgs<-XY_cpgs$TargetID 
EWAS <- EWAS[!fData(EWAS)$TargetID %in% XY_cpgs,] 
      
# Normalizacion 
boxplot(log(methylated(EWAS)), las=2, cex.axis=0.7, ylab="log Beta-val", main="Pre-
normalization Methylated" ) 
boxplot(log(unmethylated(EWAS)), las=2, cex.axis=0.7, ylab="log Beta-val", main="Pre-
normalization Unmethylated") 
EWAS_D <-  dasen(EWAS) 
boxplot(log(methylated(EWAS_D)), las=2, cex.axis=0.7,ylab="log Beta-val", 
main="Normalization Methylated"  ) 
boxplot(log(unmethylated(EWAS_D)), las=2, cex.axis=0.7,ylab="log Beta-val", 
main="Normalization Unmethylated"  ) 
 
# Estimar Betas # 
manifest<- fData(EWAS_D) 
 
betas <- estimateBeta(EWAS_D,returnType="matrix") 
betas<-as.data.frame(betas) 
 
dat<- pData(EWAS_D) 
 
# Establecer Casos y controles # 
case<-colnames(betas)[grep("CA",dat$Group)] 
cases<-which(colnames(betas) %in% case) 
controls<-which(!colnames(betas) %in% case) 
 
# Diferencias entre dos grupos con variable Continua # Man-withney 
betas<- data.frame(betas,wilcox.npaired=apply(betas,1,function(y) { 
  y <- 
try(wilcox.test(as.numeric(y[controls]),as.numeric(y[cases]),paired=F)$p.value) 
  return(ifelse(class(y)=="numeric",y,1)) 
})) 
 
# Corrección estadística de la significacncia de las diferencias encontradas# 
betas<- data.frame(betas,bonfe=p.adjust(betas$wilcox.npaired,"bonferroni")) 
selected_cpgs_bonfe<-subset(betas, betas$bonfe<0.05) 
betas<- data.frame(betas,FDR=p.adjust(betas$wilcox.npaired,"fdr")) 
selected_cpgs_FDR<-subset(betas, betas$FDR<0.05) 
 
########################################################################### 
ewas_D <- as(EWAS_D, "MethylSet") 
cpgs <- rownames(gene_ord30)[1:6] 
par(mfrow=c(2,3)) 
plotCpg(ewas_D, cpg=cpgs, pheno=dat$Group) 
########################################################################### 
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# Selección de los mejores p-val # 
pval<-data.frame(betas$wilcox.npaired) 
genes<-data.frame(pval$betas.wilcox.npaired, 
fData(EWAS_D)$TargetID,fData(EWAS_D)$CHR,  
                  fData(EWAS_D)$MAPINFO, fData(EWAS_D)$UCSC_REFGENE_NAME, 
                  fData(EWAS_D)$REGULATORY_FEATURE_GROUP) 
 
pval_ord<-order(genes$pval.betas.wilcox.npaired) 
gene_ord<-genes[pval_ord,] 
gene_ord30 <- gene_ord [1:30,] 
gene_ord_sig <- gene_ord [1:58,] 
 
manhatan<-
data.frame(genes$fData.EWAS_D..TargetID,genes$fData.EWAS_D..CHR,genes$fData.EWAS_D..M
APINFO, genes$pval.betas.wilcox.npaired) 
map<-data.frame(genes$fData.EWAS_D..CHR,genes$fData.EWAS_D..TargetID, 
"0",genes$fData.EWAS_D..MAPINFO) 
 
write.table(manhatan, file="manhattan.txt", row.names = FALSE, 
            col.names = FALSE, quote=FALSE, sep="\t") 
write.table(map, file="map.map", row.names = FALSE, 
            col.names = FALSE, quote=FALSE, sep="\t") 
write.table(gene_ord30, file="genes_ord30.txt",quote=FALSE, sep="\t") 
write.table(gene_ord_sig, file="genes_ord_sig.txt",quote=FALSE, sep="\t") 
      
###################################################################### 
 
Manterner<- 
c("cg07925064","cg06726262","cg09332091","cg18002896","cg03548645","cg25236894","ch.1
8.400468R","cg09533145","cg18127204","cg01348374","cg12181407","cg14630099","cg187698
18","cg03654504","cg10318528","cg14258853","cg15107336","cg17737641","cg20908919","cg
25146814","cg26322913","cg21285198","cg27093242","cg16126516","cg16338278","cg2284954
3","cg05036153","cg06419964","cg18997433","cg00660096","cg03523799","cg09131511","cg1
1539992","cg19113641","cg19861460","cg12096506","cg27073311","cg27553667","cg00571292
","cg16149238","cg16575530","cg24997845","cg03331123","cg07480754","cg11841562","cg17
761538","cg24083496","cg24532669","cg26243551","cg26529771","cg00048178","cg05141341"
,"cg09156140","cg12624825","cg14235701","cg14793406","cg22296322","cg25629418") 
EWAS_D_mantener <- EWAS_D[featureNames(EWAS_D) %in% Manterner,] 
ewas <- as(EWAS_D_mantener, "MethylSet") 
data <- pData(EWAS_D_mantener) 
densityPlot(ewas, sampGroups = data$Group, main = "Methylation Density Distribution", 
xlab = "Methylation Level (Beta-val)") 
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Appendix B:   
pval TargetID CHR UCSC Ref. Gene Name 
8,54E-07 cg07925064 16 LOC100130015 
3,03E-06 cg06726262 17 ZNF286A 
6,97E-06 cg09332091 19 
 
6,97E-06 cg18002896 8 RHPN1 
9,58E-06 cg03548645 14 TRAF3 
1,12E-05 cg25236894 17 RPAIN 
1,12E-05 ch.18.400468R 18 
 
1,31E-05 cg09533145 5 ADAMTS2 
1,52E-05 cg18127204 17 MYOCD 
1,77E-05 cg01348374 3 
 
2,05E-05 cg12181407 5 
 
2,05E-05 cg14630099 6 HLA-DOA 
2,05E-05 cg18769818 11 ARAP1 
2,38E-05 cg03654504 1 GRIK3 
2,75E-05 cg10318528 4 SFRP2 
2,75E-05 cg14258853 12 TMTC1 
3,18E-05 cg15107336 19 XRCC1 
3,18E-05 cg17737641 12 LGR5 
3,18E-05 cg20908919 12 PRICKLE1 
3,18E-05 cg25146814 17 
 
3,18E-05 cg26322913 14 MAP4K5; ATL1 
3,66E-05 cg21285198 1 TMEM88B 
3,66E-05 cg27093242 3 TRIM71 
4,21E-05 cg16126516 19 PPP5C 
4,21E-05 cg16338278 11 ALDH3B2 
4,21E-05 cg22849543 20 LOC284749 
4,84E-05 cg05036153 9 SLC34A3 
4,84E-05 cg06419964 17 MRM1 
4,84E-05 cg18997433 4 DHX15 
5,55E-05 cg00660096 17 
 
5,55E-05 cg03523799 13 FARP1 
5,55E-05 cg09131511 2 FAP 
5,55E-05 cg11539992 17 RHBDF2 
5,55E-05 cg19113641 2 GDF7 
5,55E-05 cg19861460 19 ZNF581; ZNF580 
6,36E-05 cg12096506 11 
 
6,36E-05 cg27073311 6 RBM16 
6,36E-05 cg27553667 15 GABRG3 
7,27E-05 cg00571292 8 UBE2W 
7,27E-05 cg16149238 2 KLHL29 
7,27E-05 cg16575530 2 LOC339788 
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7,27E-05 cg24997845 2 STAT1 
8,30E-05 cg03331123 5 
 
8,30E-05 cg07480754 16 
 
8,30E-05 cg11841562 5 SLC27A6 
8,30E-05 cg17761538 8 MGC70857; LRRC24 
8,30E-05 cg24083496 2 
 
8,30E-05 cg24532669 11 BRMS1 
8,30E-05 cg26243551 6 SFRS18 
8,30E-05 cg26529771 16 CDH15 
9,46E-05 cg00048178 6 GFOD1 
9,46E-05 cg05141341 7 ZMIZ2 
9,46E-05 cg09156140 5 C5orf34 
9,46E-05 cg12624825 9 LOC100128076 
9,46E-05 cg14235701 9 FAM69B 
9,46E-05 cg14793406 12 
 
9,46E-05 cg22296322 7 
 
9,46E-05 cg25629418 12 LRTM2 
 
